Amyloidosis (overview) E85.9/L99.0

Author: Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 16.11.2026

Dieser Artikel auf Deutsch

History
This section has been translated automatically.

Virchow, 1854; Lubarsch, 1929; Gutmann, 1928; Freudenthal, 1930; Gottron, 1950;

Definition
This section has been translated automatically.

Heterogeneous group of diseases whose common feature is the mostly extracellular deposition (in some localized amyloidoses also intracellular deposition) of a misfolded protein complex that is not degradable for the organism. Usually, the formed proteins are present in solute form and are proteolytically degradable. Disorders of protein folding(beta-fold conformation) lead to the formation of now insoluble fibrillar complexes (amyloid fibrils). These fibrils cannot be phagocytized because they cannot be attacked by the macrophage system due to their conformational peculiarities. Thus, amyloid accumulates in various organs (kidney, liver, spleen, adrenal glands, gastrointestinal tract), including the skin (see cutaneous amyloidoses below) with characteristic clinical and histological changes. To date, > 30 amyloidogenic proteins are known. Remark: Amyloid biding is comparable to the pathogenic protein deposits in beta-sheet structure that characterize prion diseases.

Classification
This section has been translated automatically.

 Systemic (Generalized) Amyloidosis

  • Non-hereditary systemic amyloidoses (95%) 
    • AA-type amyloidosis (the most common form of amyloidosis)
    • AL-type amyloidosis (immunoglobulin-associated amyloidosis)
    • β2-microglobulin-associated amyloidosis (hemodialysis patients)

Hereditary (systemic/localized) amyloidoses (=familial amyloidoses/transthyretin amyloidosis; AFib; AAPoA1/2; Alys; Agel; Aß; ACys; ABri/ADan; familial primary localized cutaneous amyloidosis) (5%) 

Localized amyloidoses (symptoms at the site of amyloid synthesis)

Literature
This section has been translated automatically.

  1. Breathnach SM (1988) Amyloid and amyloidosis. J Am Acad Dermatol 18: 1-16
  2. Cohen AS, Jones LA (1993) Advances in Amyloidosis. Curr Opin Rheumatol 5: 62-76
  3. Dubrey S et al (2014) The transthyretin amyloidoses: advances in therapy. Postgraduate Med J doi: 10.1136/postgradmedj-2014-133224.
  4. Hung CC et al (2003) Unusual skin manifestation of cutaneous amyloidosis. Dermatology 207: 65-67
  5. Lubarsch O (1899) Hyaline and amyloid degeneration. Erg allg Path 4: 449-460
  6. Moon AO et al (2003) Nodular amyloidosis: review and long-term f-up of 16 cases. Arch Dermatol 139: 1157-1159
  7. Santos-Juanes J et al (2004) Nodular primary localized cutaneous amyloidosis. J Eur Acad Dermatol Venereol 18: 224-226
  8. Virchow R (1854) On the course of amyloid degeneration. Virch Arch 8: 364-368
  9. Woollons A et al (2001) Nodular localized primary cutaneous amyloidosis: a long-term follow-up study. Br J Dermatol 145: 105-109

Disclaimer

Please ask your physician for a reliable diagnosis. This website is only meant as a reference.

Authors

Last updated on: 16.11.2026